# A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

> **NCT07060365** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **AstraZeneca**

## Conditions studied

- Advanced/Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Saruparib

## Key facts

- **NCT ID:** NCT07060365
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-09-02
- **Primary completion:** 2025-12-19
- **Final completion:** 2025-12-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07060365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07060365, "A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07060365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*